scispace - formally typeset
H

Hui Yu

Researcher at University of New Mexico

Publications -  9
Citations -  76

Hui Yu is an academic researcher from University of New Mexico. The author has contributed to research in topics: Human genome & RNA editing. The author has an hindex of 4, co-authored 9 publications receiving 38 citations.

Papers
More filters
Journal ArticleDOI

Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA.

TL;DR: It is shown that non-coding RNAs perform as well as messenger RNAs in predicting survival of cancer patients, which reinforces the potential prognostic value of non-CodingRNAs.
Journal ArticleDOI

Genomic Positional Dissection of RNA Editomes in Tumor and Normal Samples.

TL;DR: This study quantitatively analyzed human genome-wide RNA editing events derived from tumor or normal tissues and identified hyper RNA edited genes (protein-coding genes, lincRNAs, and pseudogenes) that embody a large portion of cancer prognostic predictors.
Journal ArticleDOI

Expression correlation attenuates within and between key signaling pathways in chronic kidney disease.

TL;DR: A global expression correlation attenuation within and between key signaling pathways in chronic kidney disease is discovered, with pathway Regulation of nuclear SMAD2/3 signaling demonstrating the most remarkable intra-pathway correlation rewiring.
Journal ArticleDOI

SMDB: pivotal somatic sequence alterations reprogramming regulatory cascades.

TL;DR: This work presents the first database that hosts millions of somatic motifs ascribed to a variety of sequence alteration mechanisms, including those for important transcription factors, RNA-binding proteins, miRNA seeds and miRNA–mRNA 3′-UTR target motifs.
Journal ArticleDOI

MutEx: a multifaceted gateway for exploring integrative pan-cancer genomic data.

TL;DR: This work constructed MutEx, a pan-cancer integrative genomic database that records the relationships among gene expression, somatic mutation and survival data for cancer patients and provides several application examples, including top somatic mutations associated with the most extensive expression dysregulation in breast cancer.